Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP783714.RAPcg1SnPBZHytP2As2-U4D6L4aWjrbH7ePXozGO052D0130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP783714.RAPcg1SnPBZHytP2As2-U4D6L4aWjrbH7ePXozGO052D0130_assertion type Assertion NP783714.RAPcg1SnPBZHytP2As2-U4D6L4aWjrbH7ePXozGO052D0130_head.
- NP783714.RAPcg1SnPBZHytP2As2-U4D6L4aWjrbH7ePXozGO052D0130_assertion wasGeneratedBy ECO_0000203 NP783714.RAPcg1SnPBZHytP2As2-U4D6L4aWjrbH7ePXozGO052D0130_provenance.
- NP783714.RAPcg1SnPBZHytP2As2-U4D6L4aWjrbH7ePXozGO052D0130_assertion wasDerivedFrom befree-2016 NP783714.RAPcg1SnPBZHytP2As2-U4D6L4aWjrbH7ePXozGO052D0130_provenance.
- NP783714.RAPcg1SnPBZHytP2As2-U4D6L4aWjrbH7ePXozGO052D0130_assertion SIO_000772 20035238 NP783714.RAPcg1SnPBZHytP2As2-U4D6L4aWjrbH7ePXozGO052D0130_provenance.
- NP783714.RAPcg1SnPBZHytP2As2-U4D6L4aWjrbH7ePXozGO052D0130_assertion evidence source_evidence_literature NP783714.RAPcg1SnPBZHytP2As2-U4D6L4aWjrbH7ePXozGO052D0130_provenance.
- NP783714.RAPcg1SnPBZHytP2As2-U4D6L4aWjrbH7ePXozGO052D0130_assertion description "[Serum proteomics and mutations in the epidermal growth factor receptor (EGFR) and KRAS have been associated with benefit after therapy with EGFR-targeted therapies in non-small cell lung cancer, but all three have not been evaluated in any one study.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP783714.RAPcg1SnPBZHytP2As2-U4D6L4aWjrbH7ePXozGO052D0130_provenance.